JP5122279B2 - 放射線を用いた治療及び/又は化学療法の前に癌を事前感作する方法、及び新規のサイトカイン混合物 - Google Patents

放射線を用いた治療及び/又は化学療法の前に癌を事前感作する方法、及び新規のサイトカイン混合物 Download PDF

Info

Publication number
JP5122279B2
JP5122279B2 JP2007519321A JP2007519321A JP5122279B2 JP 5122279 B2 JP5122279 B2 JP 5122279B2 JP 2007519321 A JP2007519321 A JP 2007519321A JP 2007519321 A JP2007519321 A JP 2007519321A JP 5122279 B2 JP5122279 B2 JP 5122279B2
Authority
JP
Japan
Prior art keywords
range
ratio
therapeutic agent
tumor
interleukin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007519321A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008505082A (ja
JP2008505082A5 (https=
Inventor
アヤル テイラー,
Original Assignee
セル‐サイ コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セル‐サイ コーポレイション filed Critical セル‐サイ コーポレイション
Publication of JP2008505082A publication Critical patent/JP2008505082A/ja
Publication of JP2008505082A5 publication Critical patent/JP2008505082A5/ja
Application granted granted Critical
Publication of JP5122279B2 publication Critical patent/JP5122279B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/2006IL-1
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/191Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/193Colony stimulating factors [CSF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/2013IL-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/217IFN-gamma
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2007519321A 2004-06-29 2005-06-28 放射線を用いた治療及び/又は化学療法の前に癌を事前感作する方法、及び新規のサイトカイン混合物 Expired - Fee Related JP5122279B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/878,563 2004-06-29
US10/878,563 US20050002899A1 (en) 2003-07-03 2004-06-29 Method of pre-sensitizing cancer prior to treament with radiation and/or chemotherapy and a novel cytokine mixture
PCT/US2005/022678 WO2006004633A2 (en) 2004-06-29 2005-06-28 A method of pre-sensitizing cancer prior to treament with radiation and/or chemotherapy and a novel cytokine mixture

Publications (3)

Publication Number Publication Date
JP2008505082A JP2008505082A (ja) 2008-02-21
JP2008505082A5 JP2008505082A5 (https=) 2008-08-21
JP5122279B2 true JP5122279B2 (ja) 2013-01-16

Family

ID=35783284

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007519321A Expired - Fee Related JP5122279B2 (ja) 2004-06-29 2005-06-28 放射線を用いた治療及び/又は化学療法の前に癌を事前感作する方法、及び新規のサイトカイン混合物

Country Status (8)

Country Link
US (1) US20050002899A1 (https=)
EP (1) EP1773368B1 (https=)
JP (1) JP5122279B2 (https=)
CN (1) CN101014354A (https=)
AU (1) AU2005260053A1 (https=)
CA (1) CA2571598A1 (https=)
ES (1) ES2581978T3 (https=)
WO (1) WO2006004633A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6896879B2 (en) * 2003-07-03 2005-05-24 Cel-Sci Corporation Method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture
CA2593648A1 (en) * 2005-01-10 2006-07-13 Research Development Foundation Targeted chimeric molecules for cancer therapy
CN100344325C (zh) * 2005-10-17 2007-10-24 华南师范大学 一种治疗宫颈癌的药物及其制备方法与应用
US20080131396A1 (en) * 2006-12-04 2008-06-05 Cel-Sci Corp. Method for altering the CD4/CD8 ratio and the mononuclear cellular infiltrate into a tumor
CN102166347B (zh) * 2011-04-02 2013-12-11 广州市恺泰生物科技有限公司 一种白细胞介素-12的药物新用途
WO2025019822A1 (en) * 2023-07-19 2025-01-23 Istari Oncology, Inc. Methods of treatment with a chimeric poliovirus in patients with glioblastoma

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0789588B1 (en) * 1994-11-17 2005-01-19 University Of South Florida Method for making a medicament for treating secondary immunodeficiency
AU2002232560A1 (en) * 2000-10-27 2002-05-06 Immuno-Rx, Inc Vaccine immunotherapy for immune suppressed patients
US6896879B2 (en) * 2003-07-03 2005-05-24 Cel-Sci Corporation Method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture
US20060257357A1 (en) * 2005-05-10 2006-11-16 Cel-Sci Corporation Method for modulating HLA class II tumor cell surface expression with a cytokine mixture

Also Published As

Publication number Publication date
WO2006004633A2 (en) 2006-01-12
CA2571598A1 (en) 2006-01-12
AU2005260053A1 (en) 2006-01-12
CN101014354A (zh) 2007-08-08
US20050002899A1 (en) 2005-01-06
ES2581978T3 (es) 2016-09-08
JP2008505082A (ja) 2008-02-21
EP1773368B1 (en) 2016-05-04
EP1773368A2 (en) 2007-04-18
WO2006004633A3 (en) 2006-03-16
EP1773368A4 (en) 2009-08-05

Similar Documents

Publication Publication Date Title
CN1845757B (zh) 细胞因子混合物在制备由于预敏化癌症的药物中的用途和用于治疗癌症的药物组合物
EP2684569A1 (en) A composition for treatment of advanced prostate cancer
JP2006306898A (ja) 二次性免疫不全症の治療法
US20070166279A1 (en) Method for modulating hla class ii tumor cell surface expression with a cytokine mixture
HU215389B (hu) Eljárás hatóanyagként IL-4-et tartalmazó tömött tumorok kezelésére alkalmas gyógyszerkészítmények előállítására
EP1753452B1 (en) A method for altering the cd4/cd8 ratio and the mononuclear cellular infiltrate into a tumor
JP5122279B2 (ja) 放射線を用いた治療及び/又は化学療法の前に癌を事前感作する方法、及び新規のサイトカイン混合物
KR100225322B1 (ko) 종양괴사인자와 인터루킨-4의 상승작용 조성물
US20080131396A1 (en) Method for altering the CD4/CD8 ratio and the mononuclear cellular infiltrate into a tumor
JPH09510737A (ja) 化学療法剤を増強するためのil−4の使用
KR102732912B1 (ko) K-ras 특이적 활성화 T 세포를 포함하는 폐 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
HK1105858A (en) A method of pre-sensitizing cancer prior to treament with radiation and/or chemotherapy and a novel cytokine mixture
WO2006101535A1 (en) Inhibition of proteasome function to potentiate the proapoptotic and antitumor activity of cytokines
HK1120214A (en) A method for modulating hla class ii tumor cell surface expression with a cytokine mixture
HK1096846A (en) A method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture
KR20240130054A (ko) K-ras 특이적 활성화 T 세포를 포함하는 폐 유두상 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR20240125907A (ko) K-ras 특이적 활성화 T 세포를 포함하는 흑색종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
HK1106983A (en) A method for altering the cd4/cd8 ratio and the mononuclear cellular infiltrate into a tumor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080630

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110712

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120808

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120904

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120925

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121024

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151102

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 5122279

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees